Oncology Institute, Inc. (TOI) Asset Writedowns and Impairment (2021 - 2023)

Oncology Institute (TOI) has 3 years of Asset Writedowns and Impairment data on file, last reported at $2.0 million in Q4 2023.

• Quarterly Asset Writedowns and Impairment rose 2587.84% year-over-year to $2.0 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $2.0 million (up 1794.29% YoY) and the FY2023 annual result came in at $2.0 million, up 324.37% from the prior year.
• Asset Writedowns and Impairment rose to $2.0 million in Q4 2023, from $33000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $2.0 million in Q4 2023 to a low of -$722000.0 in Q2 2021.
• A 3-year average of $189000.0 and a median of $74000.0 in 2022 frame the typical range for Asset Writedowns and Impairment.
• The widest YoY moves for Asset Writedowns and Impairment: up 2587.84% in 2023, down 102.86% in 2023.
• Tracing TOI's Asset Writedowns and Impairment over 3 years: stood at $250000.0 in 2021, then plunged by 70.4% to $74000.0 in 2022, then soared by 2587.84% to $2.0 million in 2023.
• The last three Asset Writedowns and Impairment figures came in at $2.0 million (Q4 2023), $33000.0 (Q3 2023), and -$3000.0 (Q2 2023), per Business Quant data.